You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Iodine-131 Tositumomab in Lymphoma

ID: 6-19 Jan 2007
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Hematology Disease Site Group

Patient Population

Adult patients with lymphoma of any type, at any stage of disease, and for any level of performance status.

Research Question(s)

In adult patients with lymphoma of any type, at any stage of disease, and for any level of performance status:

  1. What are the benefits associated with treatment with Iodine-131 (131I) tositumomab? Outcomes of interest include survival, quality of life, time-to-progression, response duration, and response rate.
  2. What is the toxicity associated with the use of 131I tositumomab?
  3. Which patients are more or less likely to benefit from treatment with 131I tositumomab?
  4. Is performance of imaging or dosimetry required for treatment with 131I tositumomab to be safe and effective?
pdf download Summary (PDF) (192.49 KB)
pdf download Full Report (PDF) (824.55 KB)